Total amount: € 0,00
Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus
Online ISSN 1827-1723
Battaglieri M. 1, Cantoni A. 2
1 Cardiorespiratory Section, Geriatric Department, Istituto Pio Albergo Trivulzio, Milan, Italy
2 Geriatrics, Istituto Pio Albergo Trivulzio, Milan, Italy
Bosentan is a dual endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH). This paper presents our experience with bosentan therapy in a chronic obstructive pulmonary disease patient with concomitant severe pulmonary hypertension. The therapy implemented led to a gradual reduction in pulmonary artery pressure values and an improvement in a 6-minute walk test. Good tolerance and a safety profile in line with controlled clinical studies were also observed.